BACKGROUND: The study was conducted to evaluate the technical and clinical performance of the VITROS® Immunodiagnostic Products 25-OH Vitamin D Total Assay, and compare it with the performance of five marketed automated assays and a liquid chromatography/mass spectrometry reference method (LC-MS/MS). METHODS: Three hundred patient serum samples were used to compare the correlation of the VITROS® 25-OH Vitamin D Total Assay with both the other immunoassays and the LC-MS/MS method, using Passing-Bablok regression and Bland-Altman analyses. Concordance of the diagnosis of vitamin D status was calculated to test the agreement between the different assays. In addition, samples containing vitamin D2 were used to test the assay's ability to detect the D2 form of the vitamin. RESULTS AND CONCLUSIONS: These results from the VITROS® 25-OH Vitamin D Total Assay generally correlated well with those from most of the marketed immunoassays. Cross-reactivity of the D2 form was calculated as being close to 100%. Additionally, we found substantial variability in performance amongst the various assays, which suggests the need for optimisation and recalibration of commercial methods.
BACKGROUND: The study was conducted to evaluate the technical and clinical performance of the VITROS® Immunodiagnostic Products 25-OH Vitamin D Total Assay, and compare it with the performance of five marketed automated assays and a liquid chromatography/mass spectrometry reference method (LC-MS/MS). METHODS: Three hundred patient serum samples were used to compare the correlation of the VITROS® 25-OH Vitamin D Total Assay with both the other immunoassays and the LC-MS/MS method, using Passing-Bablok regression and Bland-Altman analyses. Concordance of the diagnosis of vitamin D status was calculated to test the agreement between the different assays. In addition, samples containing vitamin D2 were used to test the assay's ability to detect the D2 form of the vitamin. RESULTS AND CONCLUSIONS: These results from the VITROS® 25-OH Vitamin D Total Assay generally correlated well with those from most of the marketed immunoassays. Cross-reactivity of the D2 form was calculated as being close to 100%. Additionally, we found substantial variability in performance amongst the various assays, which suggests the need for optimisation and recalibration of commercial methods.
Authors: Stephen A Wise; Johanna E Camara; Carolyn Q Burdette; Grace Hahm; Federica Nalin; Adam J Kuszak; Joyce Merkel; Ramón A Durazo-Arvizu; Emma L Williams; Christian Popp; Christian Beckert; Jan Schultess; Glen Van Slooten; Carole Tourneur; Camille Pease; Ravi Kaul; Alfredo Villarreal; Marcelo Cidade Batista; Heather Pham; Alex Bennett; Eugene Jansen; Dilshad Ahmed Khan; Mark Kilbane; Patrick J Twomey; James Freeman; Neil Parker; Sohail Mushtaq; Christine Simpson; Pierre Lukas; Étienne Cavalier; Christopher T Sempos Journal: Anal Bioanal Chem Date: 2021-08-25 Impact factor: 4.142